Premium
Predictors of long‐term drug survival for infliximab in psoriasis
Author(s) -
Magis Q.,
Jullien D.,
GaudyMarqueste C.,
Baumstark K.,
Viguier M.,
Bachelez H.,
Guibal F.,
Delaporte E.,
Karimova E.,
Montaudié H.,
Boye T.,
Aubin F.,
BeylotBarry M.,
Richard M.A.
Publication year - 2017
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13747
Subject(s) - medicine , infliximab , psoriasis , methotrexate , retrospective cohort study , drug , survival analysis , observational study , surgery , disease , dermatology , pharmacology
Background Limited information is available regarding factors associated with long‐term drug survival of infliximab for psoriasis in real life. Objectives The main aim pf this study was to identify predictors of long‐term (>12 months) drug survival among patients treated with infliximab for psoriasis in a real‐world clinical setting. Methods Retrospectively collected data, relating to disease, patient characteristics and treatment procedures, in a multicentre observational cohort of patients with moderate‐to‐severe plaque psoriasis treated with infliximab at eight university hospitals, 120 of whom maintained a response to infliximab for more than 12 months, were compared with prospectively collected data in the same centres from 54 patients who experienced secondary loss of response within a 12‐month period. Results Mean duration of drug survival of infliximab in patients with long‐term drug survival was 41.12 months ± 20.64 SD vs. 8.5 months ± 2.43 SD in patients with a secondary loss of response. Multivariate analysis identified greater disease severity at treatment onset ( PASI score >12) ( OR = 5.18, 95% CI : 1.60–16.77, P = 0.006), high levels of initial psoriasis clearance ( PASI ‐90 reduction or equivalent) ( OR = 18.50, 95% CI : 4.56–74.45, P = 0.0001) and combination with methotrexate ( OR = 13.15, 95% CI : 1.46–118.79, P = 0.022) as independent predictors of long‐term drug survival and sustained efficacy of infliximab. Conclusion Positive predictors for long‐term drug survival of infliximab in real life were identified. Their impact on treatment management should be addressed in further prospective trials.